Dopamine cytotoxicity involves both oxidative and nonoxidative pathways in SH-SY5Y cells: Potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of parkinson's disease

Parkinson's Disease

Volumn 2014, Issue , 2014, Pages

  Banerjee, Kalpita ^a,b   Munshi, Soumyabrata ^a,c   Sen, Oishimaya ^a   Pramanik, Vishmadeb ^d   Roy Mukherjee, Tapasi ^a,e   Chakrabarti, Sasanka ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b Burke Research Institute   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d Anthropological Survey of India   (India)

^e NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA SYNUCLEIN; DOPAMINE; LACTACYSTIN;

ARTICLE; CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84899522351     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2014/878935     Document Type: Article

References (52)

1. Olanow C. W., Tatton W. G., Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience 1999 22 123 144 2-s2.0-0032936755 10.1146/annurev.neuro.22.1.123 (Pubitemid 29144883)
2. Abou-Sleiman P. M., Muqit M. M. K., Wood N. W., Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Reviews Neuroscience 2006 7 3 207 219 2-s2.0-33644543761 10.1038/nrn1868 (Pubitemid 43292466)
3. Dawson T. M., Dawson V. L., Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003 302 5646 819 822 2-s2.0-0242363670 10.1126/science.1087753 (Pubitemid 37339614)
4. Gerlach M., Riederer P., Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. Journal of Neural Transmission 1996 103 8-9 987 1041 2-s2.0-0029845140 10.1007/BF01291788 (Pubitemid 26383833)
5. Lotharius J., Dugan L. L., O'Malley K. L., Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. Journal of Neuroscience 1999 19 4 1284 1293 2-s2.0-0033557640 (Pubitemid 29088911)
6. Borland M. K., Trimmer P. A., Rubinstein J. D., Keeney P. M., Mohanakumar K. P., Liu L., Bennett J. P. Jr., Chronic, low-dose rotenone reproduces lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Molecular Neurodegeneration 2008 3 1, article 21 2-s2.0-66249144714 10.1186/1750-1326-3-21
7. Kowall N. W., Hantraye P., Brouillet E., Beal M. F., McKee A. C., Ferrante R. J., MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport 2000 11 1 211 213 2-s2.0-0034676997 (Pubitemid 30053420)
8. Xiong N., Huang J., Zhang Z., Zhang Z., Xiong J., Liu X., Jia M., Wang F., Chen C., Cao X., Liang Z., Sun S., Lin Z., Wang T., Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS ONE 2009 4 11 2-s2.0-70849084551 10.1371/journal.pone.0007878 e7878
9. Blum D., Torch S., Lambeng N., Nissou M.-F., Benabid A.-L., Sadoul R., Verna J.-M., Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology 2001 65 2 135 172 2-s2.0-0034993599 10.1016/S0301-0082(01)00003-X (Pubitemid 32524182)
10. Panov A., Dikalov S., Shalbuyeva N., Taylor G., Sherer T., Greenamyre J. T., Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. Journal of Biological Chemistry 2005 280 51 42026 42035 2-s2.0-29644447278 10.1074/jbc.M508628200 (Pubitemid 43023171)
11. Jana S., Sinha M., Chanda D., Roy T., Banerjee K., Munshi S., Patro B. S., Chakrabarti S., Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease. Biochimica et Biophysica Acta: Molecular Basis of Disease 2011 1812 6 663 673 2-s2.0-79954581538 10.1016/j.bbadis.2011.02.013
12. Lee C. S., Han J. H., Jang Y. Y., Song J. H., Han E. S., Differential effect of catecholamines and MPP+ on membrane permeability in brain mitochondria and cell viability in PC12 cells. Neurochemistry International 2002 40 4 361 369 2-s2.0-0036160538 10.1016/S0197-0186(01)00069-9 (Pubitemid 34131611)
13. Stokes A. H., Lewis D. Y., Lash L. H., Jerome W. G. III, Grant K. W., Aschner M., Vrana K. E., Dopamine toxicity in neuroblastoma cells: role of glutathione depletion byL-BSO and apoptosis. Brain Research 2000 858 1 1 8 2-s2.0-0033965940 (Pubitemid 30105774)
14. Lai C.-T., Yu P. H., Dopamine- and L- β -3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells: effects of oxidative stress and antioxidative factors. Biochemical Pharmacology 1997 53 3 363 372 2-s2.0-0031042677 10.1016/S0006-2952(96)00731-9 (Pubitemid 27114606)
15. Walkinshaw G., Waters C. M., Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. Journal of Clinical Investigation 1995 95 6 2458 2464 2-s2.0-0029051317
16. Youn Y. C., Kwon O. S., Han E. S., Song J. H., Shin Y. K., Lee C. S., Protective effect of boldine on dopamine-induced membrane permeability transition in brain mitochondria and viability loss in PC12 cells. Biochemical Pharmacology 2002 63 3 495 505 2-s2.0-0036471027 10.1016/S0006-2952(01)00852-8 (Pubitemid 34169729)
17. Weingarten P., Bermak J., Zhou Q.-Y., Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF- B and lack of protection by anti-oxidants. Journal of Neurochemistry 2001 76 6 1794 1804 2-s2.0-0035107766 10.1046/j.1471-4159.2001.00190.x (Pubitemid 32221119)
18. Pedrosa R., Soares-da-Silva P., Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. British Journal of Pharmacology 2002 137 8 1305 1313 2-s2.0-0036945244 10.1038/sj.bjp.0704982 (Pubitemid 36071748)
19. McNaught K. S. P., Belizaire R., Jenner P., Olanow C. W., Isacson O., Selective loss of 20S proteasome α -subunits in the substantia nigra pars compacta in Parkinson's disease. Neuroscience Letters 2002 326 3 155 158 2-s2.0-0037025111 10.1016/S0304-3940(02)00296-3 (Pubitemid 34722448)
20. McNaught K. S. P., Belizaire R., Isacson O., Jenner P., Olanow C. W., Altered proteasomal function in sporadic Parkinson's disease. Experimental Neurology 2003 179 1 38 46 2-s2.0-0037227397 10.1006/exnr.2002.8050 (Pubitemid 36062617)
21. Zhou W., Huribert M. S., Schaack J., Prasad K. N., Freed C. R., Overexpression of human α -synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Research 2000 866 1-2 33 43 2-s2.0-0034595728 10.1016/S0006-8993(00)02215-0 (Pubitemid 30313005)
22. Tabrizi S. J., Orth M., Max Wilkinson J., Taanman J.-W., Warner T. T., Mark Cooper J., Schapira A. H. V., Expression of mutant α -synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics 2000 9 18 2683 2689 2-s2.0-0034326816
23. Bisaglia M., Greggio E., Maric D., Miller D. W., Cookson M. R., Bubacco L., Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC neuroscience 2010 11, article 41 2-s2.0-77951915408 10.1186/1471-2202-11-41
24. Hasegawa T., Matsuzaki-Kobayashi M., Takeda A., Sugeno N., Kikuchi A., Furukawa K., Perry G., Smith M. A., Itoyama Y., α -Synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease. FEBS Letters 2006 580 8 2147 2152 2-s2.0-33645244513 10.1016/j.febslet.2006.03.018
25. Banerjee K., Sinha M., Pham C. L. L., Jana S., Chanda D., Cappai R., Chakrabarti S., α -Synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: Implications in Parkinson's disease. FEBS Letters 2010 584 8 1571 1576 2-s2.0-77951290337 10.1016/j.febslet.2010.03.012
26. Sung J. Y., Kim J., Paik S. R., Park J. H., Ahn Y. S., Chung K. C., Induction of neuronal cell death by Rab5A-dependent endocytosis of α -synuclein. Journal of Biological Chemistry 2001 276 29 27441 27448 2-s2.0-0035920226 10.1074/jbc.M101318200
27. Yermolaieva O., Xu R., Schinstock C., Brot N., Weissbach H., Heinemann S. H., Hoshi T., Methionine sulfoxide reductase A protects neuronal cells against brief hypoxia/reoxygenation. Proceedings of the National Academy of Sciences of the United States of America 2004 101 5 1159 1164 2-s2.0-0842299564 10.1073/pnas.0308215100 (Pubitemid 38182659)
28. Kitazawa M., Anantharam V., Kanthasamy A., Kanthasamy A. G., Dieldrin promotes proteolytic cleavage of poly(ADP-ribose) polymerase and apoptosis in dopaminergic cells: protective effect of mitochondrial anti-apoptotic protein Bcl-2. NeuroToxicology 2004 25 4 589 598 2-s2.0-2942542719 10.1016/j.neuro.2003. 09.014 (Pubitemid 38739115)
29. 2 release from activated human leukocytes using a dihydroxyphenoxazine derivative. Journal of Immunological Methods 1997 202 2 133 141 2-s2.0-0031588923 10.1016/S0022- 1759(96)00244-X (Pubitemid 27128755)
30. Khan F. H., Saha M., Chakrabarti S., Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain Research 2001 895 1-2 245 249 2-s2.0-0035937522 10.1016/S0006-8993(00)03284-4 (Pubitemid 32231162)
31. Choi H. J., Kim S. W., Lee S. Y., Hwang O., Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. Journal of Neurochemistry 2003 86 1 143 152 2-s2.0-0037632905 10.1046/j.1471-4159.2003.01808.x (Pubitemid 36753855)
32. Sherer T. B., Betarbet R., Stout A. K., Lund S., Baptista M., Panov A. V., Cookson M. R., Greenamyre J. T., An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α -synuclein metabolism and oxidative damage. Journal of Neuroscience 2002 22 16 7006 7015 2-s2.0-0037104723 (Pubitemid 35379158)
33. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., Protein measurement with the Folin phenol reagent. The Journal of biological chemistry 1951 193 1 265 275 2-s2.0-71849104860
34. Altman D. G., Bland J. M., Standard deviations and standard errors. British Medical Journal 2005 331 7521, article 903 2-s2.0-26944463905
35. Pardo B., Mena M. A., Fahn S., de Yebenes J. G., Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Movement Disorders 1993 8 3 278 284 2-s2.0-0027268723 (Pubitemid 23212535)
36. Pardo B., Mena M. A., Casarejos M. J., Paino C. L., De Yebenes J. G., Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Research 1995 682 1-2 133 143 2-s2.0-0029053242 10.1016/0006-8993(95)00341-M
37. Offen D., Ziv I., Sternin H., Melamed E., Hochman A., Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Experimental Neurology 1996 141 1 32 39 2-s2.0-0030249286 10.1006/exnr.1996.0136 (Pubitemid 26317179)
38. Kuhn D. M., Arthur R. Jr., Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. Journal of Neuroscience 1998 18 18 7111 7117 2-s2.0-0032531095 (Pubitemid 28425798)
39. Kuhn D. M., Arthur R. E. Jr., Thomas D. M., Elferink L. A., Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. Journal of Neurochemistry 1999 73 3 1309 1317 2-s2.0-0032842040 10.1046/j.1471-4159.1999. 0731309.x (Pubitemid 29395493)
40. Khan F. H., Sen T., Chakrabarti S., Dopamine oxidation products inhibit Na+, K+-ATPase activity in crude synaptosomal-mitochondrial fraction from rat brain. Free Radical Research 2003 37 6 597 601 2-s2.0-0037613733 10.1080/1071576031000115651 (Pubitemid 36603669)
41. Gómez-Santos C., Barrachina M., Giménez-Xavier P., Dalfó E., Ferrer I., Ambrosio S., Induction of C/EBP β and GADD153 expression by dopamine in human neuroblastoma cells: relationship with α -synuclein increase and cell damage. Brain Research Bulletin 2005 65 1 87 95 2-s2.0-13244261152 10.1016/j.brainresbull.2004.11.008 (Pubitemid 40186934)
42. Jowaed A., Schmitt I., Kaut O., Wüllner U., Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. Journal of Neuroscience 2010 30 18 6355 6359 2-s2.0-77951842993 10.1523/JNEUROSCI.6119-09.2010
43. Parihar M. S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P., Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. International Journal of Biochemistry and Cell Biology 2009 41 10 2015 2024 2-s2.0-68949151944 10.1016/j.biocel.2009.05.008
44. Hayashita-Kinoh H., Yamada M., Yokota T., Mizuno Y., Mochizuki H., Down-regulation of α -synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochemical and Biophysical Research Communications 2006 341 4 1088 1095 2-s2.0-32344444326 10.1016/j.bbrc.2006.01.057 (Pubitemid 43221777)
45. Hashimoto M., Hsu L. J., Rockenstein E., Takenouchi T., Mallory M., Masliah E., α -synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. Journal of Biological Chemistry 2002 277 13 11465 11472 2-s2.0-0037192865 10.1074/jbc.M111428200 (Pubitemid 34952915)
46. Musgrove R. E. J., King A. E., Dickson T. C., Neuroprotective upregulation of endogenous alpha-synuclein precedes ubiquitination in cultured dopaminergic neurons. Neurotoxicity Research 2011 19 4 592 602 2-s2.0-79958164975 10.1007/s12640-010-9207-x
47. Cookson M. R., alpha-Synuclein and neuronal cell death. Molecular Neurodegeneration 2009 4, article 9 10.1186/1750-1326-4-9
48. Seo J.-H., Rah J.-C., Choi S. H., Shin J. K., Min K., Kim H.-S., Park C. H., Kim S., Kim E.-M., Lee S.-H., Lee S., Suh S. W., Suh Y.-H., Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. The FASEB Journal 2002 16 13 1826 1828 2-s2.0-0036832421
49. Shehadeh L., Mitsi G., Adi N., Bishopric N., Papapetropoulos S., Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. Movement Disorders 2009 24 2 204 210 2-s2.0-61649109808 10.1002/mds.22306
50. Wills J., Jones J., Haggerty T., Duka V., Joyce J. N., Sidhu A., Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Experimental Neurology 2010 225 1 210 218 2-s2.0-77955664249 10.1016/j.expneurol.2010.06.017
51. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M., Goedert M., α -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6469 6473 2-s2.0-0032568534 10.1073/pnas.95.11.6469 (Pubitemid 28249037)
52. Edwards T. L., Scott W. K., Almonte C., Burt A., Powell E. H., Beecham G. W., Wang L., Züchner S., Konidari I., Wang G., Singer C., Nahab F., Scott B., Stajich J. M., Pericak-Vance M., Haines J., Vance J. M., Martin E. R., Genome-Wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for parkinson disease. Annals of Human Genetics 2010 74 2 97 109 2-s2.0-77951185469 10.1111/j.1469-1809.2009.00560.x